TMCnet News
Chan Soon-Shiong Institute for Molecular Medicine and the University of Oxford Establish Partnership to Create the First Center for Genomic and Proteomic Medicine in the United Kingdom to Benefit NHS Cancer Patients as Part of a $50M CommitmentLONDON --(Business Wire)-- The Chan Soon-Shiong Institute for Molecular Medicine (CSSIOMM) and the University of Oxford announced a partnership to establish the Chan Soon-Shiong Oxford Center for Molecular Medicine (CSSOCMM), the first of its kind in the United Kingdom designed to support the delivery of individualized, data-driven molecular based medicine for the benefit of NHS cancer patients. The Chan Soon-Shiong Institute has made an initial commitment of $50M to advance clinical cancer care in the UK through genomic and proteomic driven diagnoses. These funds will provide doctors with large-scale sequencing capabilities for patient-level genomic, epigenomic, proteomic, and digital pathology data capture as well as novel tools and super-computing technology to support critical decision making for cancer treatment. The Center will work in close collaboration with the Oxford University Hospitals NHS Trust. Today's announcement is being made at a press conference in London at which the Minister for Life Sciences, George Freeman MP will preside. Commenting on the announcement, he said: "This investment is a sign that Britain is leading the world in the exciting new field of Genomic Medicine. Breakthroughs in our understanding of how genetics determines how disease really works in patients is crucial to generating new treatments and medicines. "This investment highlights the international confidence in the UK's ability to develop better and more personalized cancer treatments that can make a real difference to patients - especially in rare disease and cancer. The Prime Minister and I are determined to make Britain the best place in the world to discover and develop 21st century medicines. That's why we have invested in the 100,000 Genomes project, to create the world's first large scale hub of genetic and disease data. This partnership with the Institute for Molecular Medicine will help us to bring new treatments to NHS patients." "Along with the University of Oxford, we are living our commitment to clinicians and patients alike," said Dr. Patrick Soon-Shiong, founder and chairman of the Chan Soon-Shiong Institute for Molecular Medicine. "Using the most advanced, sophisticated tools imaginable, we're on a mission to solve the mystery of cancer, and establish an adaptive learning system where the power of one can inform many. The infrastructure to manage big data must be established to enable a national network of clinical scientists in the UK and a portion of the $50M commitment will be used to fund the capital needs to ensure that patients throughout England could benefit from this genomic platform, with the remaining $35M provided to support the operations of the Chan Soon-Shiong Oxford Center for Molecular Medicine at Oxford." This is the third partnership announced by the Chan Soon-Shiong Institute of Molecular Medicine this year. The Providence Health System, one of the largest hospital systems spanning 5 Western states in America, and Phoenix Children's Hospital were the two recipients of CSSIOMM grants in the past 6 months. Th CSSOCMM will receive a $35M grant to utilize next-generation patient information systems needed to support the acquisition and usage of high-quality sequencing data. This will enable new approaches to therapeutic decisions, drug discovery capabilities, machine learning predictive modelling and support for clinical trials to evaluate the impact of therapeutic interventions in large patient populations through the CSSOCMM. "Through this partnership, we are furthering our ability to use cutting edge technologies to allow radically new approaches to cancer care," said Professor Sir John Bell FRS, Regius Professor of Medicine at the University of Oxford. "We will gain new understanding of how large amounts of genomic and other molecular data can be combined with clinical data to tell us much more about a patient's cancer. The data will provide a rich resource for cancer research, drive the development of new drugs and support the design of clinical trials. And ultimately, the treatment course a patient receives will be determined by the characteristics of the cancer they have." Professor Andrew Hamilton, Vice-Chancellor of the University of Oxford, said: "The ability to understand the particular genetic and molecular changes underlying a patient's cancer holds great potential for cancer medicine. The Chan Soon-Shiong Oxford Center for Molecular Medicine will not only use the latest techniques to characterize tumor samples from patients, but investigate how this can be used to guide the treatments individual patients receive. That is a truly exciting prospect, and the partnership between the Chan Soon-Shiong Institute of Molecular Medicine and the University of Oxford will have a pioneering role to play in making personalized medicine a reality for cancer patients." The CSSOCMM will be co-located with the new Precision Cancer Medicine Institute, also announced today, where the clinical applications of its research will take place. It will have strong links with the Target (News - Alert) Discovery Institute and Big Data Institute, all part of the major investment in cancer diagnosis and treatment being made by the University of Oxford over the next five years, the most comprehensive investment in this area of any UK University. "This partnership will evaluate and provide comprehensive molecular diagnostics from genomics to proteomics integrated with clinical data for cancer patients with the aim to identify the right treatment for the right patient at the right time," said Anna Schuh, Head of the Oxford BRC/NHS Molecular Diagnostics Center and Director of Molecular Diagnostics for the Department of Oncology, University of Oxford. About The Chan Soon-Shiong Institute of Molecular Medicine (CSSIOMM) Chan Soon-Shiong Institute of Molecular Medicine (CSSIOMM) is a division of Chan Soon-Shiong NantHealth Foundation, a 501(c)(3) non-profit medical research organization focused on transforming medical practice by facilitating digital molecular diagnosis. CSSIOMM is building a coalition dedicated to collaborating with health care, academic, government, and private sector partners to enable evidence based and molecularly driven, clinical decisions. The mission of CSSIOMM is to facilitate transformation of health systems to focus on health not just healthcare, to create a culture of caring and to support the development of next generation clinical scientists. The goal of the CSSIOMM is to improve the lives of the people and to enable sustainable health systems for the future. About NantOmics: NantOmics is a leading medical diagnostic company dedicated to providing actionable intelligence and molecularly-driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular diagnostics company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analyzing both normal and tumor cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and conducting quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis. For more information please visit www.nantomics.com and follow Dr. Soon-Shiong on Twitter (News - Alert) @solvehealthcare. About Oxford University Oxford University's Medical Sciences Division is one of the largest biomedical research centers in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine, and it is home to the UK's top-ranked medical school. From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery. A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu. Oxford is also renowned for its large-scale studies which examine the role of factors such as smoking, alcohol and diet on cancer, heart disease and other conditions.
|
